Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy.
The intervention treatment with the immuno-adjuvant levamisole was given in 14 persistently bacteriologically positive lepromatous cases who had had adequate chemotherapy for over 5 years. There was a temporary conversion of the early lepromin reaction in a majority of the patients with a corresponding improvement in clinical and bacteriological status. However, the lepromin response was short lived. Most patients had become bacteriologically negative at the end of 1 year. No adverse effects due to levamisole therapy were encountered.
D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007916:Lepromin; D007918:Leprosy / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007916:Lepromin; D007978:Levamisole